Side-by-side · Research reference

PancragenvsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/39 cited

BPhase 3AUTO-DRAFTED10/40 cited

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

Pancragen

Tesofensine

Primary target

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

Yes — preserves physiological glucose-insulin response

—

Origin

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

Pancragen

Tesofensine

Primate dose (rhesus macaque)

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

—

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

—

Route

IntramuscularGoncharova 2015

—

Frequency

Once daily for 10 daysGoncharova 2014

Once daily, morning

Treatment cycle

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

—

Evidence basis

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Phase 2b + ongoing Phase 3Astrup 2008

Diabetes model

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

—

Standard dose

—

0.25–0.5 mg / dayAstrup 2008

Lower / starter dose

—

0.125 mg / day

Duration

—

24 weeks per studied cycle

Form

—

Oral capsule

Timing

—

Morning to avoid sleep disruption

Half-life

—

~9 days (very long)

04Side Effects & Safety

Parameter

Pancragen

Tesofensine

Reported adverse events

None documented in primate studies

—

Tolerability

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

—

Human safety data

No published human trials; clinical use limited to Russian gerontology protocols

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Pancragen

—

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

Pancragen

Tesofensine

1. Reconstitution

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

Oral capsule (investigational; not commercial).

2. Route

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

Swallow whole with water, morning only.

3. Timing

No specific timing constraints documented. Administered once daily in primate protocols.

Morning to mitigate insomnia. Do not dose evening.

4. Cycle structure

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

Room temp ≤25 °C, dry place.

5. Caveat

—

Monitor BP + HR + mood. Avoid stimulants + MAOIs.